S&D Co (260970) Q2 2024 earnings summary

Executive summary

• Specializes in functional food ingredients and health supplements, with a focus on natural and bioactive materials for food and cosmetics.

• No subsidiaries or affiliates; operates independently with a single business focus.

• Recent business purpose expansion to enable future diversification, though no new business lines have launched yet.

Financial highlights

• H1 2024 revenue: ₩52.6 billion, down from ₩88.3 billion in H1 2023.

• Operating income for H1 2024: ₩8.7 billion, down from ₩12.9 billion year-over-year.

• Net income for H1 2024: ₩7.1 billion, compared to ₩11.9 billion in H1 2023.

• Basic EPS for H1 2024: ₩1,967, down from ₩2,925 in H1 2023.

• Gross margin remains robust, but both sales and profits declined year-over-year.

Outlook and guidance

• No explicit forward guidance provided; business purpose expanded for potential future diversification.

• Continues to focus on R&D and product innovation in functional food and health supplement sectors.